iShares Biotechnology ETF (NASDAQ:IBB) Stock Cross Above Fifty Day Moving Average – What’s Next?

iShares Biotechnology ETF (NASDAQ:IBB) shares crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $207.81 and traded as high as $210.01. iShares Biotechnology ETF shares last traded at $208.69, with a volume of 765,470 shares changing hands.

iShares Biotechnology ETF Stock Up 2.0%

The business’s fifty day moving average is $208.27 and its two-hundred day moving average is $184.36.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 18th. Shareholders of record on Tuesday, September 15th were given a $0.0112 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.0%. The ex-dividend date was Tuesday, September 15th. This is a negative change from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238.

Institutional Investors Weigh In On iShares Biotechnology ETF

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in shares of iShares Biotechnology ETF by 10.8% during the first quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after acquiring an additional 707,343 shares during the period. Royal Bank of Canada increased its position in iShares Biotechnology ETF by 1.0% in the first quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock worth $124,464,000 after purchasing an additional 7,434 shares during the period. Cetera Investment Advisers increased its position in iShares Biotechnology ETF by 9.4% in the first quarter. Cetera Investment Advisers now owns 128,530 shares of the financial services provider’s stock worth $21,702,000 after purchasing an additional 10,994 shares during the period. Albion Financial Group UT increased its position in iShares Biotechnology ETF by 1.0% in the third quarter. Albion Financial Group UT now owns 120,782 shares of the financial services provider’s stock worth $25,428,000 after purchasing an additional 1,147 shares during the period. Finally, Henshaw Capital LLC bought a new stake in iShares Biotechnology ETF during the 1st quarter worth about $20,262,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.